PYYX 8-K
Pyxus International, Inc. (PYYX)
8-K
2023-08-10
For: 2023-08-10
View Original
Added on
April 06, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 10, 2023
(Exact name of Registrant, as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission file number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
(919 ) 379-4300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
The information in this report shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation by reference language contained therein, except as shall be expressly set forth by specific reference in such a filing.
| Item 2.02 | Results of Operations and Financial Condition | ||||
On August 10, 2023 , Pyxus International, Inc. issued a press release announcing its operating and financial results for the three months ended June 30, 2023. The press release is furnished as Exhibit 99.1 hereto.
| Item 9.01 | Financial Statements and Exhibits | ||||
(d) Exhibits
Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 10, 2023
| PYXUS INTERNATIONAL, INC. | ||||||||
| By: | /s/ William L. O’Quinn, Jr. | |||||||
| William L. O’Quinn, Jr. | ||||||||
| Senior Vice President – Chief Legal | ||||||||
| Officer and Secretary | ||||||||
Exhibit 99.1
| Pyxus International, Inc. | Tel: 919 379 4300 |  | ||||||||||||
| 6001 Hospitality Court | Fax: 919 379 4346 | |||||||||||||
| Suite 100 | www.pyxus.com | |||||||||||||
| Morrisville, NC 27560-2009 | ||||||||||||||
| USA | ||||||||||||||
| NEWS RELEASE | Contact: | Tomas Grigera | ||||||||||||||||||||||||
| (919) 379-4300 | ||||||||||||||||||||||||||
Pyxus International, Inc. Reports Fiscal Year 2024 First Quarter Results
Maintains Full Year Guidance
Morrisville, NC – August 10, 2023 – Pyxus International, Inc. (OTC Pink: PYYX) (“Pyxus,” the “Company,” "we," or "our"), a global value-added agricultural company, today announced results for its fiscal quarter ended June 30, 2023.
Highlights (comparisons are to the prior-year first fiscal quarter):
•Sales and other operating revenues were $477.1 million, up $133.2 million, or 38.7%.
•Operating income increased $29.4 million to $36.4 million.
•Net income was $0.8 million, improving $15.5 million.
•Adjusted EBITDA* increased $27.5 million to $43.5 million.
•For the full 2024 fiscal year, Pyxus continues to expect sales to be between $1.9 billion and $2.1 billion and adjusted EBITDA to be between $155 million and $180 million.
*Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization ("Adjusted EBITDA") is not a measure of results under generally accepted accounting principles in the United States ("GAAP"). Adjusted EBITDA expected for fiscal 2024 is calculated in a manner consistent with Adjusted EBITDA for historical periods as presented in the reconciliation tables included in this press release. Because of the forward looking nature of the estimated range of Adjusted EBITDA, it is impractical to present a quantitative reconciliation of such measure to a comparable GAAP measure, and accordingly no such GAAP measure is being presented.
"Fiscal 2024 is off to a strong start with higher tobacco prices, accelerated timing of shipments, and a favorable shift in customer mix fueling a 39% increase in revenue and improved profitability compared to the prior year," said Pieter Sikkel, Pyxus' President and CEO.
"In the first quarter of fiscal 2024, we believe we reached the peak of our fiscal 2024 tobacco purchases as we significantly accelerated our buying, using our geographic footprint to acquire tobacco inventory from multiple markets to meet higher current crop supply requirements and customer demand for fiscal 2024. Customer shipments in fiscal 2024 will utilize a higher percentage of tobacco purchased during the current fiscal year to fulfill orders compared to the prior year given our uncommitted inventory continues to be historically low.
"Our continued focus on aggressively managing our working capital provided sufficient liquidity through short-term borrowings under our foreign seasonal lines of credit, availability under the ABL Credit Facility, cash generated from operations, and cash collections from our securitized receivables to purchase larger volumes of more expensive tobacco compared to the prior year. In the first quarter of fiscal 2024, we increased our purchases of inventory by more than $100 million compared to the prior year using $40 million of incremental foreign seasonal lines of credit and our improved cash conversion cycle.
"We anticipate ongoing strong demand as undersupply conditions are expected to persist through fiscal 2024. We believe our positive first quarter results position the Company to achieve our previously announced fiscal 2024 guidance for sales between $1.9 billion and $2.1 billion and adjusted EBITDA between $155 million and $180 million. We are proud of the progress our global teams have made thus far and thank them for their unwavering commitment to our customers and their focus on achieving the Company's objectives so that together we can grow a better world."
1
Performance Summary for Three Months Ended June 30, 2023
Sales and other operating revenues increased $133.2 million, or 38.7%, to $477.1 million for the three months ended June 30, 2023 from $343.9 million for the three months ended June 30, 2022. This increase was primarily due to an 18.6% increase in leaf volume and a 17.6% increase in average price per kilo. The increase in leaf volume was primarily due to the accelerated timing of shipments from Africa and South America. The increase in average price per kilo was mainly due to higher tobacco prices.
Cost of goods and services sold increased $100.8 million, or 33.2%, to $404.0 million for the three months ended June 30, 2023 from $303.2 million for the three months ended June 30, 2022. This increase was mainly due to the increase in sales and other operating revenues. Average cost per kilo increased primarily due to undersupply conditions and inflation.
Gross profit as a percent of sales increased to 15.3% for the three months ended June 30, 2023 from 11.9% for the three months ended June 30, 2022. Average gross profit per kilo for product revenue increased 56.0% primarily due to customer mix in Africa, Asia, and Europe.
Operating income increased $29.4 million, or 420.0%, to $36.4 million for the three months ended June 30, 2023 from $7.0 million for the three months ended June 30, 2022. This increase was mainly due to higher leaf sales and other operating revenues from increased volume and average price per kilo and was partially offset by higher other expense, net, which was primarily due to higher utilization of securitization facilities.
Liquidity and Capital Resources
The Company’s liquidity requirements are affected by various factors including crop seasonality, foreign currency and interest rates, green tobacco prices, customer mix, crop size and quality. The following table summarizes the Company’s cash and available credit:
| (in millions) | June 30, 2023 | June 30, 2022 | ||||||
| Cash and cash equivalents | $ | 100.0 | $ | 165.4 | ||||
| ABL Credit Facility | 50.0 | 10.0 | ||||||
| Foreign seasonal lines of credit | 149.1 | 171.9 | ||||||
| Other long-term debt | 0.2 | — | ||||||
| Letters of credit | 4.1 | 3.9 | ||||||
| Total | $ | 303.4 | $ | 351.2 | ||||
Financial Results Investor Call
The Company will hold a conference call to report financial results for the period ended June 30, 2023, on August 10, 2023 at 9:00 A.M. ET. The dial in number for the call is (646) 960-0369 or (888) 350-3452 if outside the U.S., using conference ID 2624736. Those seeking to listen to the call may access a live broadcast on the Pyxus website. Please visit www.pyxus.com 15 minutes in advance to register.
For those who are unable to listen to the live event on August 10, 2023, a telephonic replay of the conference call will be available by dialing (647) 362-9199 or (800) 770-2030 and entering the access code 2624736.
Any replay, rebroadcast, transcript, or other reproduction of this conference call, other than the replay accessible by calling the number above, has not been authorized by Pyxus International and is strictly prohibited. Investors should be aware that any unauthorized reproduction of this conference call may not be an accurate reflection of its contents.
Cautionary Statement Regarding Forward-Looking Statements
Readers are cautioned that the statements contained in this report regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which are based on current expectations of future events, may be identified by the use of words such as "strategy," "expects," "continues," "plans," "anticipates," "believes," "will," "estimates," "intends," "projects," "goals," "targets," and other words of similar meaning. These statements also may be identified by the fact that they do not relate strictly to historical or current facts. If underlying assumptions prove inaccurate, or
2
if known or unknown risks or uncertainties materialize, actual results could vary materially from those anticipated, estimated, or projected. These risks and uncertainties include those discussed in our Annual Report on Form 10-K for the year ended March 31, 2023, our most recent Quarterly Report on Form 10-Q, and in our other filings with the Securities and Exchange Commission. These risks and uncertainties include: our reliance on a small number of significant customers; continued vertical integration by our customers; global shifts in sourcing customer requirements; shifts in the global supply and demand position for tobacco products; variation in our financial results due to growing conditions, customer indications and other factors; loss of confidence in us by our customers, farmers and other suppliers; migration of suppliers who have historically grown tobacco and from whom we have purchased tobacco toward growing other crops; risks related to our advancement of inputs to tobacco suppliers to be settled upon the suppliers delivering us unprocessed tobacco at the end of the growing season; risks that the tobacco we purchase directly from suppliers will not meet our customers’ quality and quantity requirements; weather and other environmental conditions that can affect the marketability of our inventory; international business risks, including unsettled political conditions, uncertainty in the enforcement of legal obligations, including the collection of accounts receivable, fraud risks, expropriation, import and export restrictions, exchange controls, inflationary economies, currency risks and risks related to the restrictions on repatriation of earnings or proceeds from liquidated assets of foreign subsidiaries; many of our operations are located in jurisdictions that pose a high risk of potential violations of the Foreign Corrupt Practices Act; impacts of international sanctions on our ability to sell or source tobacco in certain regions; exposure to foreign tax regimes in which the rules are not clear, are not consistently applied and are subject to sudden change; fluctuations in foreign currency exchange and interest rates; competition with the other primary global independent leaf tobacco merchant and independent leaf merchants; disruption, failure or security breaches of our information technology systems; continued high inflation; we have identified material weaknesses related to our internal controls in certain prior years, and there can be no assurance that material weaknesses will not be identified in the future; regulations regarding environmental matters; risks related to our capital structure, including risks related to our significant debt and our ability to continue to finance our non-U.S. local operations with uncommitted short-term operating credit lines at the local level; our ability to continue to access capital markets to obtain long-term and short-term financing; potential failure of foreign banks in which our subsidiaries maintain deposits or the failure by such banks to transfer funds or honor withdrawals; the risk that, because our ability to generate cash depends on many factors beyond our control, we may be unable to generate the significant amount of cash required to service our indebtedness; our ability to refinance our current credit facilities at the same availability or at similar interest rates; failure to achieve our stated goals, which may adversely affect our liquidity; developments with respect to our liquidity needs and sources of liquidity; the volatility and disruption of global credit markets; failure by counterparties to derivative transactions to perform their obligations; increasing scrutiny and changing expectations from governments, as well as other stakeholders such as investors and customers, with respect to our environmental, social and governance policies, including sustainability policies; inherent risk of exposure to product liability claims, regulatory action and litigation facing our e-liquids business if its products are alleged to have caused significant loss, injury, or death; certain shareholders have the ability to exercise controlling influence on various corporate matters; reductions in demand for consumer tobacco products; risks and uncertainties related to the COVID-19 pandemic and its related shipping constraints, labor shortages and supply-chain impacts; legislative and regulatory initiatives that may reduce consumption of consumer tobacco products and demand for our services and increase regulatory burdens on us or our customers; government actions that significantly affect the sourcing of tobacco, including governmental actions to identify and assess crop diversification initiatives and alternatives to leaf tobacco growing in countries whose economies depend upon tobacco production; governmental investigations into, and litigation concerning, leaf tobacco industry buying and other payment practices; and impact of potential regulations to prohibit the sale of cigarettes in the United States other than low-nicotine cigarettes.
Non-GAAP Financial Information
This press release contains financial measures that have not been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). They include EBITDA, Adjusted EBITDA, Free Cash Flow, Adjusted Free Cash Flow, and Net Debt. Tables showing the reconciliation of historical non-GAAP financial measures are attached to the release. The range of Adjusted EBITDA anticipated for fiscal year ending March 31, 2024 is calculated in a manner consistent with the presentation of Adjusted EBITDA in the attached tables. Because of the forward-looking nature of the estimated range of Adjusted EBITDA, it is impractical to present a quantitative reconciliation of such measure to a comparable GAAP measure, and accordingly no such GAAP measure is being presented.
About Pyxus International, Inc.
Pyxus International, Inc. is a global agricultural company with 150 years of experience delivering value-added products and services to businesses and customers. Driven by a united purpose—to transform people’s lives, so that together we can grow a better world—Pyxus International, its subsidiaries and affiliates, are trusted providers of responsibly sourced, independently verified, sustainable and traceable products and ingredients. For more information, visit www.pyxus.com.
3
Condensed Consolidated Statements of Operations
| Three Months Ended | ||||||||
| June 30, | ||||||||
| (in thousands, except per share data) | 2023 | 2022 | ||||||
| Sales and other operating revenues | $ | 477,092 | $ | 343,905 | ||||
| Cost of goods and services sold | 403,947 | 303,150 | ||||||
| Gross profit | 73,145 | 40,755 | ||||||
| Selling, general, and administrative expenses | 34,063 | 34,588 | ||||||
| Other expense (income), net | 2,624 | (1,085) | ||||||
| Restructuring and asset impairment charges | 40 | 300 | ||||||
| Operating income | 36,418 | 6,952 | ||||||
| Loss on deconsolidation/disposition of subsidiaries | — | 599 | ||||||
| Interest expense, net | 30,844 | 25,474 | ||||||
| Income (loss) before income taxes and other items | 5,574 | (19,121) | ||||||
| Income tax expense (benefit) | 2,646 | (867) | ||||||
| Loss (income) from unconsolidated affiliates | 2,158 | (3,749) | ||||||
| Net income (loss) | 770 | (14,505) | ||||||
| Net (loss) income attributable to noncontrolling interests | (34) | 158 | ||||||
| Net income (loss) attributable to Pyxus International, Inc. | $ | 804 | $ | (14,663) | ||||
| Income (loss) per share: | ||||||||
| Basic and diluted | $ | 0.03 | $ | (0.59) | ||||
| Weighted average number of shares outstanding: | ||||||||
| Basic and diluted | 25,000 | 25,000 | ||||||
4
Condensed Consolidated Balance Sheets
| (in thousands) | June 30, 2023 | June 30, 2022 | |||||||||||||||
| Assets | |||||||||||||||||
| Current assets | |||||||||||||||||
| Cash and cash equivalents | $ | 100,045 | $ | 165,441 | |||||||||||||
| Restricted cash | 5,456 | 9,495 | |||||||||||||||
| Trade receivables, net | 185,467 | 155,976 | |||||||||||||||
| Other receivables | 18,978 | 26,859 | |||||||||||||||
| Inventories, net | 1,006,437 | 980,070 | |||||||||||||||
| Advances to tobacco suppliers, net | 56,408 | 44,070 | |||||||||||||||
| Recoverable income taxes | 5,867 | 8,747 | |||||||||||||||
| Prepaid expenses | 42,132 | 44,513 | |||||||||||||||
| Other current assets | 15,500 | 16,672 | |||||||||||||||
| Total current assets | 1,436,290 | 1,451,843 | |||||||||||||||
| Investments in unconsolidated affiliates | 98,591 | 87,139 | |||||||||||||||
| Other intangible assets, net | 37,412 | 42,052 | |||||||||||||||
| Deferred income taxes, net | 8,879 | 8,871 | |||||||||||||||
| Long-term recoverable income taxes | 3,373 | 4,571 | |||||||||||||||
| Other noncurrent assets | 45,845 | 46,456 | |||||||||||||||
| Right-of-use assets | 40,280 | 35,636 | |||||||||||||||
| Property, plant, and equipment, net | 132,324 | 135,878 | |||||||||||||||
| Total assets | $ | 1,802,994 | $ | 1,812,446 | |||||||||||||
| Liabilities and Stockholders’ Equity | |||||||||||||||||
| Current liabilities | |||||||||||||||||
| Notes payable | $ | 585,408 | $ | 545,224 | |||||||||||||
| Accounts payable | 133,854 | 144,915 | |||||||||||||||
| Advances from customers | 61,297 | 46,071 | |||||||||||||||
| Accrued expenses and other current liabilities | 94,356 | 91,054 | |||||||||||||||
| Income taxes payable | 20,081 | 6,729 | |||||||||||||||
| Operating leases payable | 9,249 | 8,535 | |||||||||||||||
| Current portion of long-term debt | 42 | 13,781 | |||||||||||||||
| Total current liabilities | 904,287 | 856,309 | |||||||||||||||
| Long-term taxes payable | 4,978 | 5,783 | |||||||||||||||
| Long-term debt | 643,808 | 678,777 | |||||||||||||||
| Deferred income taxes | 10,336 | 9,925 | |||||||||||||||
| Liability for unrecognized tax benefits | 13,494 | 12,173 | |||||||||||||||
| Long-term leases | 28,219 | 26,473 | |||||||||||||||
| Pension, postretirement, and other long-term liabilities | 53,703 | 59,748 | |||||||||||||||
| Total liabilities | 1,658,825 | 1,649,188 | |||||||||||||||
| Commitments and contingencies | |||||||||||||||||
| Stockholders’ equity | |||||||||||||||||
Common Stock—no par value: | |||||||||||||||||
Authorized shares (250,000 for all periods) | |||||||||||||||||
Issued shares (25,000 for all periods) | 390,290 | 390,290 | |||||||||||||||
| Retained deficit | (257,150) | (233,476) | |||||||||||||||
| Accumulated other comprehensive income | 7,084 | 3,248 | |||||||||||||||
| Total stockholders’ equity of Pyxus International, Inc. | 140,224 | 160,062 | |||||||||||||||
| Noncontrolling interests | 3,945 | 3,196 | |||||||||||||||
| Total stockholders’ equity | 144,169 | 163,258 | |||||||||||||||
| Total liabilities and stockholders’ equity | $ | 1,802,994 | $ | 1,812,446 | |||||||||||||
5
Segment Results
Three Months Ended June 30, 2023 and 2022 | ||||||||||||||
| Three Months Ended June 30, | ||||||||||||||
| Change | ||||||||||||||
| (in thousands, except per kilo amounts) | 2023 | 2022 | $ | % | ||||||||||
| Leaf: | ||||||||||||||
| Product revenues | $ | 450,938 | $ | 322,884 | 128,054 | 39.7 | ||||||||
| Tobacco costs | 363,042 | 265,989 | 97,053 | 36.5 | ||||||||||
| Transportation, storage, and other period costs | 20,593 | 20,627 | (34) | (0.2) | ||||||||||
| Total cost of goods sold | 383,635 | 286,617 | 97,018 | 33.8 | ||||||||||
| Product revenue gross profit | 67,303 | 36,267 | 31,036 | 85.6 | ||||||||||
| Product revenue gross profit as a percent of sales | 14.9 | % | 11.2 | % | ||||||||||
| Kilos sold | 85,521 | 72,059 | 13,462 | 18.7 | ||||||||||
| Average price per kilo | $ | 5.27 | $ | 4.48 | 0.79 | 17.6 | ||||||||
| Average cost per kilo | 4.49 | 3.98 | 0.51 | 12.8 | ||||||||||
| Average gross profit per kilo | 0.78 | 0.50 | 0.28 | 56.0 | ||||||||||
| Processing and other revenues | $ | 25,495 | $ | 17,743 | 7,752 | 43.7 | ||||||||
| Processing and other revenues costs of services sold | 19,880 | 12,547 | 7,333 | 58.4 | ||||||||||
| Processing and other gross margin | 5,615 | 5,196 | 419 | 8.1 | ||||||||||
| All Other: | ||||||||||||||
| Sales and other operating revenues | $ | 659 | $ | 3,279 | (2,620) | (79.9) | ||||||||
| Cost of goods and services sold | 432 | 3,986 | (3,554) | (89.2) | ||||||||||
| Gross income (loss) | 227 | (708) | 935 | 132.1 | ||||||||||
6
Reconciliation of Certain Non-GAAP Financial Measures (1) (Unaudited)
| Three Months Ended | Fiscal Year Ended | Last Twelve Months (8) | ||||||||||||||||||
| (in thousands) | June 30, 2023 | June 30, 2022 | March 31, 2023 | March 31, 2022 | June 30, 2023 | June 30, 2022 | ||||||||||||||
| Net income (loss) attributable to Pyxus International, Inc. | $ | 804 | $ | (14,663) | $ | (39,141) | $ | (82,119) | (23,674) | $ | (85,274) | |||||||||
| Plus: Interest expense | 32,366 | 27,527 | 118,458 | 111,043 | 123,297 | 111,143 | ||||||||||||||
| Plus: Income tax expense (benefit) | 2,646 | (867) | 34,127 | 12,640 | 37,640 | 20,212 | ||||||||||||||
| Plus: Depreciation and amortization expense | 4,606 | 5,929 | 19,137 | 16,676 | 17,814 | 18,539 | ||||||||||||||
EBITDA (1) | 40,422 | 17,926 | 132,581 | 58,240 | 155,077 | 64,620 | ||||||||||||||
| Plus: Reserves for doubtful customer receivables | 135 | (830) | 426 | 4,404 | 1,391 | 3,356 | ||||||||||||||
| Plus: Other expense (income), net | 2,624 | (1,085) | 11,023 | 3,349 | 14,732 | 2,426 | ||||||||||||||
Plus: Restructuring and asset impairment charges (2) | 40 | 300 | 6,160 | 8,031 | 5,900 | 8,098 | ||||||||||||||
| Plus: Goodwill impairment | — | — | — | 32,186 | — | 32,186 | ||||||||||||||
Plus: Debt restructuring (3) | 26 | — | 5,496 | 3,550 | 5,522 | 2,335 | ||||||||||||||
Plus: Pension retirement expense (4) | — | — | 2,724 | — | 2,724 | — | ||||||||||||||
Plus: Development of and exit from non-leaf-tobacco businesses (5) | 43 | 619 | 713 | 13,589 | 137 | 12,853 | ||||||||||||||
Plus: Other adjustments (6) | 250 | (897) | (316) | 3,347 | 831 | 2,103 | ||||||||||||||
Adjusted EBITDA (1) | $ | 43,540 | $ | 16,033 | $ | 158,807 | $ | 126,696 | $ | 186,314 | $ | 127,977 | ||||||||
| Total debt | $ | 1,001,049 | $ | 1,066,945 | $ | 1,229,258 | $ | 1,237,782 | ||||||||||||
| Less: Cash and cash equivalents | 136,733 | 198,777 | 100,045 | 165,441 | ||||||||||||||||
Net Debt (1) | $ | 864,316 | $ | 868,168 | $ | 1,129,213 | $ | 1,072,341 | ||||||||||||
Net Debt /Adjusted EBITDA (1) | 5.44x | 6.85x | 6.06x | 8.38x | ||||||||||||||||
Adjusted EBITDA (1) | $ | 158,807 | $ | 126,696 | $ | 186,314 | $ | 127,977 | ||||||||||||
| Interest expense | 118,458 | 111,043 | 123,297 | 111,143 | ||||||||||||||||
| Interest coverage | 1.34x | 1.14x | 1.51x | 1.15x | ||||||||||||||||
| Net cash used in operating activities | (285,674) | (242,490) | (137,822) | (198,765) | (181,006) | (255,298) | ||||||||||||||
| Capital expenditures | (3,661) | (2,210) | (16,307) | (14,827) | (17,758) | (13,222) | ||||||||||||||
Collections from beneficial interests in securitized trade receivables (7) | 30,419 | 45,468 | 165,262 | 189,440 | 150,213 | 197,227 | ||||||||||||||
Free Cash Flow (1) | $ | (258,916) | $ | (199,232) | $ | 11,133 | $ | (24,152) | $ | (48,551) | $ | (71,293) | ||||||||
| Plus: Interest expense | 32,366 | 27,527 | 118,458 | 111,043 | 123,297 | 111,143 | ||||||||||||||
| Plus: Income tax expense (benefit) | 2,646 | (867) | 34,127 | 12,640 | 37,640 | 20,212 | ||||||||||||||
Adjusted Free Cash Flow (1) | $ | (223,904) | $ | (172,572) | $ | 163,718 | $ | 99,531 | $ | 112,386 | $ | 60,062 | ||||||||
(1) Earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA"), Free Cash Flow, Adjusted Free Cash Flow, and Net Debt are not measures of results of operations, cash flows from operations or indebtedness under generally accepted accounting principles in the United States ("U.S. GAAP") and should not be considered as an alternative to other U.S. GAAP measurements. We have presented EBITDA, Adjusted EBITDA, Free Cash Flow, Adjusted Free Cash Flow, and Net Debt to adjust for the items identified above because we believe that it would be helpful to the readers of our financial information to understand the impact of these items on our reported amounts. This presentation enables readers to better compare our results to similar companies that may not incur the impact of various items identified above. Management acknowledges that there are many items that impact a company's reported results or operating cash flows and these lists are not intended to present all items that may have impacted these items. EBITDA, Adjusted EBITDA, Free Cash Flow, Adjusted Free Cash Flow, Net Debt, and any ratios calculated based on these measures are not necessarily comparable to similarly-titled measures used by other companies or appearing in our debt obligations or agreements. EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow as presented may not equal column or row totals due to rounding.
(2) Amounts incurred during the three months ended June 30, 2023 and 2022 and fiscal years ended March 31, 2023 and 2022 included employee separation and asset impairment charges primarily related to the restructuring of certain non-leaf operations and related inventory write-offs classified within cost of goods and services sold in the Company's condensed consolidated statements of operations.
(3) Amounts incurred during the three months ended June 30, 2023 and fiscal year ended March 31, 2023 included legal and professional fees incurred in connection with the debt exchange and with the amendment and extension of the delayed-draw term loan, which transactions were completed in the fiscal year ended March 31, 2023. Amounts incurred during the fiscal year ended March 31, 2022 included consulting fees incurred in connection with the implementation of process improvements required in connection with the Company's delayed-draw term loan credit facility established in the prior fiscal year.
(4) During the fiscal year ended March 31, 2023, the Company settled benefits with vested participants in the U.S. defined benefit pension plan ("U.S. Pension Plan") that elected a lump sum payout and made a cash contribution to fully fund the U.S. Pension Plan's liabilities in preparation to purchase a group annuity contract to administer future payments to the remaining U.S. Pension Plan participants. This adjustment includes pension settlement charges incurred during the fiscal year ended March 31, 2023 and were classified as loss on pension settlement expense and selling, general, and administration expenses in the Company's condensed consolidated statements of operations.
(5) Includes the aggregate amount of certain items related to the Company's development of and subsequent exits from its non-leaf-tobacco businesses (that is, the production and sale of legal cannabis in Canada, the production and sale of industrial hemp products, including CBD extracted from industrial hemp, and the production and sale of tobacco e-liquids) to the extent such items are included in the Company's consolidated results of operations, which includes all items separately reported for such businesses in the presentation by the Company of its adjusted EBITDA in prior periods. Such items include, to the extent reflected in consolidated results, the adjusted EBITDA of the Canadian cannabis and industrial hemp operations otherwise calculated on the same basis as Adjusted EBITDA is presented in this table, loss incurred on the deconsolidation or disposition of certain of these non-leaf tobacco businesses, as applicable, and write-offs of inventory and equipment related to certain of these businesses.
(6) Includes the following items: (i) the addition of amortization of basis difference related to a former Brazilian subsidiary that is now deconsolidated following the completion of a joint venture in March 2014, (ii) the subtraction of the Adjusted EBITDA of the Company's former green leaf sourcing operation in Kenya, which is calculated on the same basis as Adjusted EBITDA presented in this table (in fiscal year 2016 the Company decided to exit green leaf sourcing in the Kenyan market as part of our restructuring program), (iii) the addition of debt retirement expense, and (iv) the subtraction of a one-time interest receipt related to a legal settlement in South America.
(7) Represents cash receipts from the beneficial interest on sold receivables under the Company's the accounts receivable securitization programs and were classified as investing activities within the consolidated statements of cash flows.
(8) Items for the twelve months ended June 30, 2023 are derived by adding the items for the three months ended June 30, 2023 as presented in the table and the fiscal year ended March 31, 2023 and subtracting the items for the three months ended June 30, 2022. Items for the twelve months ended June 30, 2022 are derived by adding the items for the three months ended June 30, 2022 and the fiscal year ended March 31, 2022 and subtracting the items for the three months ended June 30, 2021.
7